# US 2016/0355465 A1 · Novel modified curcumins and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355465 A1
- Document ID: US20160355465A1
- Status: Published application
- Kind: A1
- Application number: 15/240,630
- Filed: 2016-08-18
- Published: 2016-12-08
- Earliest claimed: 2011-10-17
- Assignees: The Research Foundation of State University of New York; Chem-Master International, Inc.
- Inventors: Lorne M. GOLUB; Hsi-ming LEE; Francis JOHNSON
- Web page: https://patentgrep.com/patent/US20160355465A1

## CPC

- C07C 235/80: having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
- A61K 8/42: Amides
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A61Q 19/00: Preparations for care of the skin
- C07C 235/74: of a saturated carbon skeleton
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

This invention provides a compound having the structure wherein α, β, A, B, and R1-R4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing of a wound, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NFκ-B activation in a population of cells.

## Claims

### Claim 1

A compound having the structure
wherein
bond α and β are each, independently, present or absent;
A is an aromatic or heteroaromatic ring; B is an aromatic or heteroaromatic ring;
R1 is pyridine, imidazol, oxazole, thiazole, pyridine, pyridazine, pyrazine, pyrimidine, morpholine, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, heterocyclyl, or
wherein R13, R14, R15, R16, and R17 are each independently, H, halogen, —OCZ3, —CZ3, —OCH2CH(OH)CH2OH, —OCH(CH2OH)2, —NO2, OCH3, —CN, —NR18R19, —SR18, —CO2R18, —OR20, —COR20, —CSR20, —NHCOR18, —SOR18, —POR17, —C(═S)R18, —C(═NH)R18, C(═NR18)R18, —C(═N)R18, —POR18, —P(═O) (OR18) (OR19), —P(OR18) (OR19), —C(═S)R18, —NHR18R19+, —C(═O)-heterocyclyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein Z is halogen, and
R18, R19, and R20 are each, independently, H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl;
R2 is H, —CH3, —OR21, —CO2R21, —CF3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein R21 is, H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, or —C(═O)-heterocyclyl; and
R3 and R4 are each independently, halogen, —NO2, —NR22R23, —NHR22R23+, —SR22, —SO2R22, —SO3R22, —OR22, —CO2R22, —CF3, —POR22, —P(═O) (OR22)(OR23), or —P(OR22) (OR23),
wherein R22 and R23 are each, H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)-heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted; and
when α and β are present, A is phenyl with R3 at the para position, B is phenyl with R4 at the para position, R2 is H, R3 is —OH or —N(CH3)2, and R4 is —OH or —N(CH3)2, then R1 is other than unsubstituted phenyl,
or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 having the structure
wherein
bond α and β are each, independently, present or absent;
X is —CH, —CR3 or N; Y is —CH, —CR4 or N;
R1 is pyridine, imidazol, oxazole, thiazole, pyridine, pyridazine, pyrazine, pyrimidine, morpholine, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, heterocyclyl, or
wherein R13, R14, R15, R16, and R17 are each independently, H, halogen, —OCZ3, —CZ3, —OCH2CH(OH)CH2OH, —OCH(CH2OH)2, —NO2, OCH3, —CN, —NR18R19, —SR18, —CO2R18, —OR20, —COR20, —CSR20, —NHCOR18, —SOR18, —POR17, —C(═S)R18, —C(═NH)R18, C(═NR18)R18, —C(═N)R18, —POR18, —P(═O) (OR18) (OR19), —P(OR18) (OR19), —C(═S)R18, —NHR18R19+, —C(═O)-heterocyclyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein Z is halogen, and
R18, R19, and R20 are each, independently, H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl;
R2 is H, —CH3, —OR21, —CO2R21, —CF3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein R21 is, H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, or —C(═O)-heterocyclyl; and
R3 and R4 are each independently, halogen, —NO2, —NR22R23, —NHR22R23+, —SR22, —SO2R22, —SO3R22, —OR22, —CO2R22, —CF3, —POR22, —P(═O) (OR22)(OR23), or —P(OR22) (OR23),
wherein R22 and R23 are each, H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)-heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted; and
when α and β are present, X is —CH, Y is —CH, R2 is H, R3 is —OH or —N(CH3)2 at the para position, and R4 is —OH or —N(CH3)2 at the para position, then R1 is other than unsubstituted phenyl,
or a salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2, wherein X is N, or a salt thereof.

### Claim 4 (depends on 2)

The compound of claim 2, wherein α and ρ are both present, or a salt thereof.

### Claim 5 (depends on 2)

The compound of claim 2 having the structure
wherein
R1 is pyridine, imidazol, oxazole, thiazole, pyridine, pyridazine, pyrazine, pyrimidine, morpholine, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, heterocyclyl, or
wherein R13, R14, R15, R16 and R17 and are each independently, H, halogen, —OCZ3, —CZ3, —OCH2CH(OH)CH2OH, —OCH(CH2OH)2, —NO2, OCH3, —CN, —NR18R19, —SR18, —CO2R18, —OR20, —COR20, —CSR20, —NHCOR18, —SOR18, —POR17, —C(═S)R18, —C(═NH)R18, C(═NR18)R18, —C(═N)R18, —POR18, —P(═O) (OR18) (OR19), —P(OR18) (OR19), —C(═S)R18, —NHR18R19+, —C(═O)-heterocyclyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein Z is halogen, and
R18, R19, and R20 are each, independently, H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl;
R2 is H or —CH3; and
R3 and R4 are each —OR22,
wherein R22 is H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)— heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5 having the structure
wherein
R1 is pyridine, imidazol, oxazole, thiazole, pyridine, pyridazine, pyrazine, pyrimidine, morpholine, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, heterocyclyl, or
wherein R13, R14, R15, R16 and R17 and are each independently, H, halogen, —OCZ3, —CZ3, —OCH2CH(OH)CH2OH, —OCH(CH2OH)2, —NO2, OCH3, —CN, —NR18R19, —SR18, —CO2R18, —OR20, —COR20, —CSR20, —NHCOR18, —SOR18, —POR17, —C(═S)R18, —C(═NH)R18, C(═NR18)R18, —C(═N)R18, —POR18, —P(═O)(OR18)(OR19), —P(OR18) (OR19), —C(═S)R18, —NHR18R19+, —C(═O)-heterocyclyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein Z is halogen, and
R18, R19, and R20 are each, independently, H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl; and
R3 and R4 are each —OR22,
wherein R22 is H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)— heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt thereof.

### Claim 7 (depends on 5)

The compound of claim 5, wherein R22 is H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)-heterocyclyl, wherein each occurrence of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted, or a salt thereof.

### Claim 8 (depends on 2)

The compound of claim 2 having the structure
wherein
X is —CH, —CR3 or N; Y is —CH, —CR4 or N;
R1 is pyridine, imidazol, oxazole, thiazole, pyridine, pyridazine, pyrazine, pyrimidine, morpholine, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl;
R2 is H or —CH3; and
R3 and R4 are each independently, halogen, —NO2, —NR22R23, —NHR22R23+, —SR22, —SO2R22, —SO3R22, —OR22, —CO2R22, —CF3, —POR22, —P(═O) (OR22)(OR23), or —P(OR22) (OR23),
wherein R22 and R23 are each, H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)-heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt thereof.

### Claim 9 (depends on 2)

The compound of claim 2 having the structure
wherein
X is —CH, —CR3 or N; Y is —CH, —CR4 or N;
R1 is
wherein R13, R14, or R15 is H, halogen, —OCZ3, —CZ3, —OCH2CH(OH)CH2OH, —OCH(CH2OH)2, —NO2, OCH3, —CN, —NR18R19, —SR18, —CO2R18, —OR20, —COR20, —CSR20, —NHCOR18, —SOR18, —POR17, —C(═S) R18, —C(═NH) R18, C(═NRs) R18, —C(═N)R18, —POR18, —P(═O) (OR18) (OR19), —P(OR18) (OR19), —C(═S)R18, —NHR18R19+, —C(═O)-heterocyclyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein Z is halogen, and
R18, R19, and R20 are each, independently, H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl;
R2 is H or —CH3; and
R3 and R4 are each independently, halogen, —NO2, —NR22R23, —NHR22R23+, —SR22, —SO2R22, —SO3R22, —OR22, —CO2R22, —CF3, —POR22, —P(═O) (OR22) (OR23), or —P(OR22) (OR23),
wherein R22 and R23 are each, H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)-heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt thereof.

### Claim 10 (depends on 9)

The compound of claim 9 having the structure
wherein
R1 is
wherein R13, R14, or R15 is H, halogen, —OCZ3, —CZ3, —OCH2CH(OH)CH2OH, —OCH(CH2OH)2, —NO2, OCH3, —CN, —NR18R19, —SR18, —CO2R18, —OR20, —COR20, —CSR20, —NHCOR18, —SOR18, —POR17, —C(═S)R18, —C(═NH) R18, C(═NR18) R18, —C(═N) R18, —POR18, —P(═O) (OR18) (OR19), —P(OR18) (OR19), —C(═S)R, —NHR18R19+, —C(═O)-heterocyclyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein Z is halogen, and
R18, R19, and R20 are each, independently, H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl; and
R3 and R4 are each independently, halogen, —NO2, —NR22R23, —NHR22R23+, —SR22, —SO2R22, —SO3R22, —OR22, —CO2R22, —CF3, —POR22, —P(═O) (OR22) (OR23), or —P(OR22) (OR23),
wherein R22 and R23 are each, H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)-heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt thereof.

### Claim 11 (depends on 10)

The compound of claim 10, wherein
R1 is
wherein R15 is H, halogen, —OCZ3, —CZ3, —OCH2CH(OH)CH2OH, —OCH(CH2OH)2, —NO2, OCH3, —CN, —NR18R19, —SR18, —CO2R18, —OR20, —COR20, —CSR20, —NHCOR18, —SOR18, —POR17, —C(═S)R18, —C(═NH)R18, C(═NR18)R18, —C(═N)R18, —POR18, —P((═O) (OR18) (OR19), —P(OR18) (OR19), —C(═S)R18, —NHR18R19+, —C(═O)-heterocyclyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein Z is halogen, and
R18, R19, and R20 are each, independently, H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl; and
R3 and R4 are each independently, halogen, —NO2, —NR22R23, —NHR22R23′, —SR22, —SO2R22, —SO3R22, —OR22, —CO2R22, —CF3, —POR22, —P(═O) (OR22) (OR23), or —P(OR22)(OR23),
wherein R22 and R23 are each, H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)-heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt thereof.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R3 and R4 are each —OR22, wherein R22 is H, —CF3, —CH3, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, heterocyclyl, or —C(═O)-heterocyclyl, and
wherein each occurrence in the compound of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt thereof.

### Claim 13 (depends on 12)

The compound of claim 12, wherein R22 is H.

### Claim 14 (depends on 13)

The compound of claim 13, having the structure
or a salt thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1.

### Claim at position 16

16-54. (canceled)
